Through these mechanisms, roflumilast, an oral selective PDE4 inhibitor approved for clinical use in patients with severe chronic obstructive pulmonary disease, prevents the release of NETs from neutrophils adhered on fibrinogen and challenged with bacterial endotoxin (Totani et al., 2016). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.